In the case of lung cancer, prior research has demonstrated a decrease in CRTAC1 expression in lung adenocarcinoma tissues compared to normal tissues11, with elevated levels of CRTAC1 enhancing the chemosensitivity of non-small cell lung cancer (NSCLC) to cisplatin therapy12. This evidence concerns the gene CRTAC1 and lung cancer.